DOI: https://doi.org/10.36347/sjmcr.2025.v13i04.038

Pages: 732-734

Background: Chemical castration by LHRH analogues is a cornerstone treatment for advanced prostate cancer, but it is associated with numerous side effects impacting quality of life. Objective: To evaluate the prevalence of these effects in a cohort of Moroccan patients. Methods: Retrospective, single-center study of 75 patients who received chemical castration for at least six months, from January 2023 to December 2024, with data extracted from medical records. Results: The most frequent side effects were hot flashes (82.7%) and erectile dysfunction (73.3%). Asthenia and mood disorders were observed in 64% and 50.7% of patients, respectively. Musculoskeletal pain was present in 45.3%, gynecomastia in 24%, and weight gain in approximately 37%. Conclusion: These results highlight the need for rigorous monitoring and a personalized approach to the management of side effects related to chemical castration by LHRH analogues, with the involvement of multidisciplinary healthcare professionals.